293 related articles for article (PubMed ID: 24127469)
1. Off-label topical calcineurin inhibitor use in children.
Manthripragada AD; Pinheiro SP; MaCurdy TE; Saneinejad S; Worrall CM; Kelman JA; Graham DJ
Pediatrics; 2013 Nov; 132(5):e1327-32. PubMed ID: 24127469
[TBL] [Abstract][Full Text] [Related]
2. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
3. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
Sunderkötter C; Weiss JM; Bextermöller R; Löffler H; Schneider D
J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
[TBL] [Abstract][Full Text] [Related]
4. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
5. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
6. [Prescription of topical immunomodulators].
Rosenzweig M
Ugeskr Laeger; 2009 Aug; 171(35):2472-6. PubMed ID: 19732534
[TBL] [Abstract][Full Text] [Related]
7. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns.
Horii KA; Simon SD; Liu DY; Sharma V
Pediatrics; 2007 Sep; 120(3):e527-34. PubMed ID: 17766497
[TBL] [Abstract][Full Text] [Related]
8. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
Kapoor R; Hoffstad O; Bilker W; Margolis DJ
Pediatr Dermatol; 2009; 26(6):682-7. PubMed ID: 20199441
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
10. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
[TBL] [Abstract][Full Text] [Related]
11. Innovative use of topical calcineurin inhibitors.
Lin AN
Dermatol Clin; 2010 Jul; 28(3):535-45. PubMed ID: 20510763
[TBL] [Abstract][Full Text] [Related]
12. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
[TBL] [Abstract][Full Text] [Related]
13. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.
Tennis P; Gelfand JM; Rothman KJ
Br J Dermatol; 2011 Sep; 165(3):465-73. PubMed ID: 21466537
[TBL] [Abstract][Full Text] [Related]
16. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
17. [Current aspects of the therapy with topical calcineurin inhibitors].
Enderlein E; Meller S; Rieker J; Ruzicka T; Homey B
Hautarzt; 2005 Oct; 56(10):937-41. PubMed ID: 16142499
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
19. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
Thaçi D; Salgo R
Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun; 16(2):58, 60-62. PubMed ID: 17992459
[TBL] [Abstract][Full Text] [Related]
20. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
